Research & Development

Asahi Kasei Pharma is focused on the discovery and development of new medicines that address unmet medical needs using proven drug discovery techniques and leading-edge technologies. In particular, we are addressing the increasing unmet medical needs of maturing societies and their aging populations, particularly in the fields of musculoskeletal disorders and pain management.

Research and development of pioneering drug treatments

Asahi Kasei Pharma's Elcitonin™ synthetic calcitonin derivative led the way for new therapies in osteoporosis. Our Bredinin™ immunosuppressant is recognized as a vanguard treatment for a number of indications including rheumatoid arthritis. The Teribone™ osteoporosis therapeutic agent is the result of research to exploit the effect of human parathyroid hormone (PTH) on osteoblasts to promote bone formation. To improve quality of treatment, we are advancing research and development in the next generation of drugs for various musculoskeletal disorders, including rheumatoid arthritis and osteoporosis.

Main Areas of Research

Pain Management
Musculoskeletal Disorders
Bone disease
Rheumatoid arthritis
Critical Care Medicine
Hematological disorders
Page Top